Impact of Levosimendan treatment on chronic heart failure

被引:3
作者
von Haehling, S
Diller, GP
Anker, SD
机构
关键词
D O I
10.1016/j.amjcard.2004.05.078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1105 / 1105
页数:1
相关论文
共 6 条
[1]   Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study [J].
Anker, SD ;
Negassa, A ;
Coats, AJS ;
Afzal, R ;
Poole-Wilson, PA ;
Cohn, JN ;
Yusuf, S .
LANCET, 2003, 361 (9363) :1077-1083
[2]  
Cleland John G F, 2004, Expert Rev Cardiovasc Ther, V2, P9, DOI 10.1586/14779072.2.1.9
[3]   Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals [J].
Odaka, C ;
Mizuochi, T .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 121 (03) :515-522
[4]   Anemia in chronic heart failure: Pathogenetic mechanisms [J].
Okonko, DO ;
Anker, SD .
JOURNAL OF CARDIAC FAILURE, 2004, 10 (01) :S5-S9
[5]   Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure [J].
Parissis, JT ;
Adamopoulos, S ;
Antoniades, C ;
Kostakis, G ;
Rigas, A ;
Kyrzopoulos, S ;
Iliodromitis, E ;
Kremastinos, D .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (10) :1309-1312
[6]   Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway [J].
Romeo, F ;
Li, DY ;
Shi, M ;
Mehta, JL .
CARDIOVASCULAR RESEARCH, 2000, 45 (03) :788-794